Navigation Links
Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection
Date:11/10/2008


- Gene Signal International, a Biotech Company Registered in

Switzerland, Will Move its Headquarter to the EPFL, in Lausanne,

- Gene Signal is Addressing Various Issues Related to Neovascularisation,

- Gene Signal is Working on a Portfolio of Ophthalmologic Indications,

With One Now in Phase III Trials

- Gene Signal Will Present its Interim Results at the Annual Meeting of

the American Academy of Ophtalmologist in Atlanta, USA, the

Largest Scientific Convention in this Field

Gene Signal, a biotech company registered in Switzerland, is currently starting the Phase III study of GS-101, its most advanced therapeutic ophthalmic solution, for the prevention of corneal graft rejection.

Every year, over 40'000 corneal grafts are performed worldwide to cure or prevent blindness, thus making this procedure the most frequently performed transplant surgery. However, the 5 year failure rate for corneal grafts is currently around 35%. As many other graft procedures, donor grafts are always in limited supply. A failure is even more "wasteful" in this context of long waiting lines (6 months - 2 years).

One of the main reasons for graft failure is the immune response of the body. Normally, the cornea is avascular (i.e. deprived of blood vessels), protecting the donor cornea from being rejected. However, under certain circumstances, new blood vessel creation (neovascularization) occurs, inducing an immune response to the donor graft that can lead to immunological corneal graft rejection.

Currently, there is no therapy available. Gene Signal is working on new ways to prevent this syndrome. With its antisense oligonucleotide approach, it aims to block the pathways leading to the formation of blood vessels in the cornea. This approach uses short DNA fragments that specifically target and block the production of a protein that is required for the formation and growth of new blood vessels.

<
'/>"/>
SOURCE Gene Signal International SA
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Revealing the regulating mechanism behind signal transduction in the brain
2. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
3. Signalife Announces Anticipated Date of Transition to OTCBB
4. Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow
5. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
6. AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
7. Signalife Board Approves Merger
8. Signalife Announces AFL Joins NIH Education Program
9. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
10. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
11. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... DIEGO , May 23, 2013  Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City.  The ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... (OTCQB: ILIU) today issued financial and operational results for ... December 31, 2010. "We made good ... with Stanford University, data from a clinical study was ... genetics has in improving weight loss.  Our Inherent Health ...
... FRANCISCO, March 21, 2011 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) agonists and antagonists ... diseases, announced today the presentation of positive clinical ... VTX-1463 for the treatment of allergic rhinitis. The ...
... SAN CARLOS, Calif., March 21, 2011 WaferGen ... ), a leading developer of state-of-the-art genomic analysis ... innovative genomic samples preparation, today announced they will ... gene expression profiling and target enrichment to enable ...
Cached Biology Technology:Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 2Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 3Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 4Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 5Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 6Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 7VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... genetic engineering drastically reduces the time and effort ... workhorses of biotechnology, scientists are reporting. Published in ... method paves the way for more rapid development ... and other activities. , Keith Shearwin and colleagues ... the genetic material DNA into a bacterium,s genome ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... Biochemist Glenn King is searching for an alternative to ... one the world's most efficient insect predators -- spiders. ... large Australian spider with a bite that is deadly ... of venom for King's research. The spider "cooperates" by ...
... B cell chronic lymphocytic leukemia (B-CLL),is the most ... the,progressive accumulation of mature B lymphocytes in the ... that in the early stages,of disease, B-CLL is ... signals that trigger normal B cell death (apoptosis). ...
... rapid advancement of biomedical science and the development ... types of information from biomedical text has become ... quite useful for interpreting large amounts of high-throughput ... information related to gene functions from text has ...
Cached Biology News:Spider Venom Could Yield Eco-Friendly Insecticides 2Spider Venom Could Yield Eco-Friendly Insecticides 3
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Biology Products: